Key Events This Week
11 May: Stock opens at Rs.120.65, marginal gain despite Sensex decline
12 May: Sharp 5.68% drop following downgrade to Sell rating
13 May: Quarterly results show profit rebound but revenue decline; stock rallies 3.95%
14 May: Reports flat quarterly performance amid margin pressures; stock slips 1.86%
15 May: Week closes at Rs.115.00, down 0.95% on the day
Are Smruthi Organics Ltd latest results good or bad?
2026-05-14 19:19:39Smruthi Organics Ltd's latest financial results reveal a complex picture characterized by both sequential recovery and underlying challenges. In the quarter ended March 2026, the company reported net sales of ₹29.09 crores, reflecting a quarter-on-quarter growth of 30.51% from ₹22.29 crores in the previous quarter. However, this figure represents a significant year-on-year decline of 23.63% compared to ₹38.09 crores in the same quarter of the prior year, indicating persistent difficulties in revenue generation. The net profit for the same quarter stood at ₹1.07 crores, which is a decrease of 52.02% year-on-year. This decline in profitability is compounded by a higher effective tax rate, which surged to 38.51% in Q4 FY26, compared to 18.32% in the prior year. The operating margin for the quarter was reported at 13.03%, showing a modest year-on-year improvement of 0.77% but a notable contraction from the pre...
Read full news article
Smruthi Organics Ltd Reports Flat Quarterly Performance Amid Margin Pressures
2026-05-14 08:00:07Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. Despite a higher profit after tax (PAT) for the nine-month period, the company’s net sales have contracted sharply, prompting a downgrade in its Mojo Grade from Hold to Sell.
Read full news article
Smruthi Organics Q4 FY26: Profit Rebounds But Revenue Slide Continues
2026-05-13 20:46:47Smruthi Organics Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹130.00 crores, reported a sequential recovery in profitability for the quarter ending March 2026, though the underlying revenue trends remain concerning. Net profit for Q4 FY26 stood at ₹1.07 crores, marking a decline of 23.60% quarter-on-quarter from ₹1.40 crores in Q3 FY26, whilst representing a sharp 52.02% decline year-on-year from ₹2.23 crores in Q4 FY25.
Read full news article










